Difference between revisions of "Quinupristin/dalfopristin"

(Text replacement - "5 mg" to "5mg")
(Text replacement - "pruritis" to "pruritus")
Line 37: Line 37:

Revision as of 17:16, 27 October 2016


  • Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)


  • Dosage Forms: 500mg vials, diluted into 250 mL and given over 60 mins
  • Routes of Administration: IV
  • Common Trade Names: Synercid

Adult Dosing

  • VRE: 7.5mg/kg IV q8 hrs for minimum 7 days
  • skin infections: 7.5mg/kg IV q12 hrs for minimum 7 days

Pediatric Dosing

  • safety and efficacy has not been studied in children

Special Populations

  • Pregnancy Rating: B
  • Lactation risk: unknown whether secreted in human breast milk. Caution should be exercised when administering to nursing mothers. (2)

Renal Dosing

  • no adjustments for renal impairment

Hepatic Dosing

  • dosage may need to be adjusted in patients with cirrhosis, however specific dose modification is not known at this time (2)


  • Allergy to class/drug

Adverse Reactions



  • pain and inflammation at infusion site
  • arthralgias
  • nausea/vomiting/diarrhea
  • rash
  • headache
  • pruritus


  • Half-life: Quinupristin: 3 hrs; Dalfopristin: 1 hr
  • Metabolism: significantly interacts with the CYP 3A4 system.
  • Excretion: